07/16/2026
🚨 Big news in cholesterol treatment.
The FDA has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor.
In clinical trials, it lowered:
📉 LDL by ~60%
📉 ApoB by ~50%
This does not replace statins, but it gives us another powerful option for high-risk patients who need additional LDL lowering.
One important caveat: while the cholesterol-lowering results are impressive, the cardiovascular outcomes trial is still ongoing.
A major step forward in preventive cardiology.
PreventiveCardiology %